AbbVie faced a second loss in the Testosterone Replacement Therapy (TRT) bellwether trial when the jury announced a verdict of nearly $140 million in favor of the plaintiff. The verdict comprised of $140,000 as compensatory damages and $140 million as punitive damages. This was the second bellwether case to go to trial in the multidistrict litigation (MDL): 2545 in the District Court for the Northern District of Illinois, with over 6000 actions pending against AndroGel, Testim, Axiron, and other testosterone drug makers, presided by Judge Matthew F. Kennelly.
In this case, the manufacturer lost on the grounds of failing to warn the consumers and the medical community about the alleged link to heart attack and other side effects and that its aggressive marketing strategies risked the lives of thousands of men including the plaintiff, who suffered a heart attack just months after using AndroGel. AbbVie faced a small victory when claims were rejected by the jury in a state court in the month of August. AbbVie plans to appeal the $140 million verdict.
Recent News
Roundup Lawsuits in New Jersey Seek Centralization
03/04/2024 - 17:33
A request has been filed by a group of plaintiffs urging the consolidation of all Roundup lawsuits related to non-Hodgkin’s lymphom…
Learn More
Baltimore Settles in Walmart Opioid Cases
03/03/2024 - 20:48
The mayor of Baltimore, representing the City, has endorsed a statewide settlement with Walmart to address the corporation's allege…
Learn More
Opioid Crisis: Fentanyl and Meth Drive 'Fourth Wave…
02/27/2024 - 21:02
The United States is currently grappling with what some experts identify as the "fourth wave" of the opioid epidemic, presenting in…
Learn More
Oregon Re-evaluates Decriminalization Amid Opioid Crisis
02/20/2024 - 16:46
In 2020, Oregonians approved a groundbreaking ballot measure, known as Measure 110, establishing the most progressive drug law in t…
Learn More